Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analongues

Dong Wu, Yang Li, Gaojie Song, Chongyun Cheng, Rongguang Zhang, Andrzej Joachimiak, Neil Shaw, and Zhi-Jie Liu

Abstract

5,10-Methenyltetrahydrofolate synthetase (MTHFS) regulates the flow of carbon through the one-carbon metabolic network, which supplies essential components for the growth and proliferation of cells. Inhibition of MTHFS in human MCF-7 breast cancer cells has been shown to arrest the growth of cells. Absence of the three-dimensional structure of human MTHFS (hMTHFS) has hampered the rational design and optimization of drug candidates. Here, we report the structures of native hMTHFS, a binary complex of hMTHFS with ADP, hMTHFS bound with the N5-iminium phosphate reaction intermediate, and an enzyme-product complex of hMTHFS. The N5-iminium phosphate captured for the first time in our crystal structure unravels a unique strategy used by hMTHFS for recognition of the substrate and provides structural basis for the regulation of enzyme activity. Binding of N10-substituted folate analogues places Y152 in the middle of the channel connecting ATP binding site with the substrate binding pocket, precluding the positioning of γ-phosphate for a nucleophilic attack. Using the structures of hMTHFS as a guide, we have probed the role of residues surrounding the active site in catalysis by mutagenesis. The ensemble of hMTHFS structures and the mutagenesis data yield a coherent picture of the MTHFS active site, determinants of substrate specificity, and new insights into the mechanism of inhibition of hMTHFS.

Introduction

The folate-dependent one-carbon metabolic network supplies carbon for the synthesis of purines, thymidine, and amino acids (Fig. 1; refs. 1, 2). Because these components are essential for the growth and proliferation of cells, the folate-dependent one-carbon metabolic network is a prime target for the development of anticancer therapeutics (3, 4). Several enzymes functioning in the network have been targeted successfully for the treatment of carcinomas. Methotrexate, one of the most successful antifolate to be administered in cancer chemotherapy (5), inhibits a key enzyme of the one-carbon metabolic network, dihydrofolate reductase, which catalyzes the conversion of dihydrofolate to tetrahydrofolate. Similarly, colorectal and pancreatic cancers are routinely treated by administration of the pyrimidine analogue 5-fluorouracil (5-FU), which inhibits thymidylate synthase (TS; ref. 6). TS converts deoxyuridylic acid to deoxythymidylic acid using a carbon donated by 5,10-methyltetrahydrofolate (Fig. 1). This conversion is essential for DNA synthesis (7). To increase the clinical efficiency of the treatment, 5-formyltetrahydrofolate is often coadministered along with 5-FU. The beneficial effect of administering 5-formyltetrahydrofolate during the therapy with 5-FU is a consequence of the 5,10-methenyltetrahydrofolate synthetase (MTHFS)—catalyzed conversion of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate, which is further metabolized to 5,10-methyltetrahydrofolate (Fig. 1). Lower levels of 5,10-methenyltetrahydrofolate have been shown to increase the dissociation of 5-FU from the ternary complex of TS and decrease the effectiveness of the pyrimidine analogue (8, 9). 5,10-Methenyltetrahydrofolate is also synthesized by serine hydroxymethyltransferase (SHMT) during conversion of serine to glycine. The activity of SHMT is regulated indirectly by MTHFS because the substrate of MTHFS, 5-formyltetrahydrofolate, inhibits SHMT (10–12). Glycinamide ribonucleotide transformylase and phosphoribosylaminimidazolecarboxamide transformylase, two other enzymes of the one-carbon network, use carbons from 10-formyltetrahydrofolate for the synthesis of purines and have also been targeted for the treatment of carcinomas (13, 14).

MTHFS catalyzes the initial irreversible conversion of 5-formyltetrahydrofolate to 5,10-methenyltetrahydrofolate (15). The reaction is ATP dependent and is subject to feedback inhibition by the product (16–18). Previous studies using nuclear magnetic resonance spectroscopy and isotope exchange methods have shown that the reaction proceeds via the formation of two intermediates (19). A nucleophilic attack by the formyl group of 5-formyltetrahydrofolate on the γ-phosphate of ATP results in the formation of the first N5-iminium phosphate intermediate. This part of the reaction is reversible. The second nucleophilic attack is intramolecular and is mounted by N10 of the N5-iminium phosphate on N5, resulting in the formation of a tetrahedral intermediate—phosphoimidazolidine. Phosphoimidazolidine is eventually broken down to the product 5,10-methenyltetrahydrofolate by phosphate elimination. The last step of the reaction impairs irreversibility to the overall reaction catalyzed by MTHFS. To date, relatively little is known about the structural basis for the mechanism of catalysis. The crystal structures of a ternary complex of MTHFS from Mycoplasma pneumoniae (mpMTHFS) with ADP and 5-formyltetrahydrofolate (20) and a binary complex of MTHFS from Bacillus anthracis (bMTHFS) with ADP (21) have been
reported. Although the ATP has been depicted as hydrolyzed and modeled as ADP and inorganic phosphate in the mpMTHFS structure, the substrate 5-formyltetrahydrofolate, rather than the product 5,10-methenyltetrahydrofolate, has been modeled in the active site. In addition, part of the 5-formyltetrahydrofolate moiety has been assigned zero occupancy. The overall structure of mpMTHFS and hMTHFS is similar, suggesting that MTHFS adopts a highly conserved fold. Attempts have been made to gain structural insights into inhibition of MTHFS based on steady-state kinetics and molecular modeling of a murine MTHFS (mMTHFS; refs. 22, 23). However, the interpretation of results is limited by the accuracy of the model of mMTHFS, which was generated by using a template that shares very low sequence identity.

Human MTHFS (hMTHFS) shares <28% sequence identity with structures of MTHFS homologues deposited in Protein Data Bank (PDB; ref. 24). In addition, several aspects of the structural basis for the mechanism of catalysis are unknown. What are the determinants of ligand specificity? Which residues are essential for catalysis? What is the structural basis for inhibition of hMTHFS by folate analogues? To begin to address these issues and provide a framework for the rational design of MTHFS inhibitors that could aid cancer chemotherapy, we have determined the structures of native hMTHFS, hMTHFS bound with ADP, hMTHFS in complex with an N5-iminium phosphate intermediate, and an enzyme-product complex of hMTHFS. Using the structures as a guide, essential residues have been mapped by site-directed mutagenesis. The structural and mutagenesis data unravel the determinants of substrate specificity and provide new insights into the mechanism of inhibition of hMTHFS.

Materials and Methods

Production of hMTHFS. MTHFS was amplified from human brain cDNA library using the following primers: 5′-TACTTCCATCCATGCT-TATTGCCGCGGCGGCGGT-3′ (forward) and 5′-TTATCCACTTCCAATGTF-TAAGCTTTGACGGTCT-3′ (reverse). The PCR product was ligated into pMCSG7 vector (25). Tobacco etch virus (TEV) protease-cleavable NH2-terminal hexa His-tagged hMTHFS was produced in Escherichia coli BL21(DE3) cells. Cells were grown in Luria-Bertani medium at 37°C until the A600 reached 0.8. The culture was first cooled at 4°C for 45 min followed by induction at 16°C with 0.2 mmol/L isopropyl-β-D-galactopyranoside for 20 h. Bacterial cells were harvested by centrifugation and lysed by sonication. Initial purification was carried out using Ni-affinity chromatography. His-tag was cleaved by treating the protein with TEV protease. Uncut protein and the TEV protease were removed by a second round of Ni-affinity chromatography. The protein was buffer exchanged into 20 mmol/L Tris-HCl (pH 8.0), 200 mmol/L NaCl, and 5 mmol/L β-mercaptoethanol using a Superdex G75 size exclusion column. After concentration, the protein (15–20 mg/mL) was immediately screened for crystallization.

MTHFS assay. The hMTHFS activity was measured by a Hitachi U-2010 spectrophotometer using [6S]-5-formyltetrahydrofolate (Sigma) as a substrate (23). hMTHFS was incubated with 0.5 mmol/L substrate in 400 μL of 50 mmol/L MES (pH 6.0), 20 mmol/L MgCl2, and 5 mmol/L ATP at 30°C for 2 min. The amount of 5,10-methenyltetrahydrofolate formed at the end of incubation period was quantitated by measuring the absorbance at 360 nm. One unit of enzyme activity was defined as the amount of 5,10-methenyltetrahydrofolate formed per minute under the assay conditions. All assays were performed in triplicates under identical conditions with appropriate controls. The protein concentration was estimated by reading the absorbance at 280 nm. An extinction coefficient of 16,055 mol/L−1 cm−1 was used to calculate the amount of protein in mg/mL.

Site-directed mutagenesis. Mutagenesis was carried out using Quick-Change site-directed mutagenesis kit (Stratagene) following the manufacturer’s instructions. All the mutations were verified by sequencing the entire length of the clone. Mutant and wild-type hMTHFS were expressed, purified, and assayed under identical conditions.

Crystallization. Crystallization screening was done at 16°C using the Mosquito (TTP Lab Tech) crystallization robot. Hanging drops (0.6 μL) contained equal amounts of protein and mother liquor was equilibrated against 50 μL of reservoir solution. After screening 400 conditions of commercially available sparse matrix screens, crystals appeared within 2 d in a solution containing 100 mmol/L HEPES (pH 6.6), 20 mmol/L MgCl2, 6H2O, 20 mmol/L NiCl2·6H2O, and 20% (w/v) PEG 3350. The crystals belonged to space group C2221 with unit cell dimensions: a = 48.70 Å, b = 145.12 Å, c = 59.21 Å; α = 90.00°, β = 90.00°, γ = 90.00°.

Crystals for the binary complex of hMTHFS with ADP were obtained by mixing the protein with 5 mmol/L ATP before setting up crystallization drops. Crystals for the N5-iminium phosphate–bound hMTHFS and enzyme-product complex of hMTHFS were obtained by mixing the protein
with 5 mmol/L 5-formyltetrahydrofolate and 5 mmol/L ATP before setting up crystallization drops. Crystals harvested after 48 h revealed density for N5-iminium phosphate, whereas crystals harvested after 72 h contained the product 10-formyltetrahydrofolate in the active site. Crystals for all the complexes were obtained under the same conditions as that of the native hMTHFS.

**Structure determination.** Crystals were frozen in liquid nitrogen before diffraction testing and data collection. Native diffraction data were collected at a wavelength of 0.979 Å at beamline 19-ID [Advanced Photon Source (APS), Argonne National Laboratory]. Data were indexed and scaled to 1.9 Å resolution using HKL2000 (26). The structure was solved by molecular replacement with BALBES (27) using the structure of mpMTHFS (PDB code 1U3G) as a search model. The asymmetric unit consists of 1 molecule of MTHFS with a solvent content of 49.8%. Data for the complexes of hMTHFS were collected using an in-house FRE++ copper rotating anode and an R-AXIS IV++ detector (Rigaku). A 1.8 Å resolution data set for the enzyme-product complex was collected at APS. The structures of the complexes were solved by molecular replacement with Phaser (28) using the native structure as a search model. All the final models were refined using PHENIX refine (29) and Refmac (30). Five percent of the unique reflections were assigned in a random fashion to the "free" set for calculation of the free \(R\) free; the remaining 95% of the reflections constituted the "working" set for calculation of the \(R\) factor (\(R\); ref. 31). Manual adjustments to the model were done using COOT (32). Details of data collection and refinement statistics are listed in Supplementary Table S1. The quality of the final model was validated using MOLPROBITY (33).

Adjustments to the model were done using COOT (32). Details of data collection and refinement statistics are listed in Supplementary Table S1. The quality of the final model was validated using MOLPROBITY (33). The coordinates and structure factors of the native, ADP-bound, N5-iminium phosphate–bound, and 10-formyltetrahydrofolate–bound hMTHFS have been deposited in the PDB under the accession code 3HXT, 3HY6, 3HY3, and 3HY4, respectively.

**Results**

**Overall structure of hMTHFS.** The final model of the apoenzyme consists of 197 residues (Table 1). Six amino acids, L21-A23 and E187-D189, are disordered and could not be traced. The secondary structural elements of hMTHFS are arranged in a single domain with a three-layer, α/β/α, sandwich architecture and a topology similar to the Rossmann fold (Fig. 2A and B). The overall structure consists of a highly twisted sheet made up of eight β strands flanked by α helices on either side. hMTHFS is made up of five α helices. Whereas helices α2 and α3 are stacked against four parallel β strands at the center, α5 is seen stacked on the opposite side of the sheet. Interestingly, helix α1 is positioned almost perpendicular to α2 and is close to the edge of the sheet. Part of α1 is seen protruding out of the main body of the protein, suggesting that it may be involved in protein-protein interactions.

To gain insights into the architecture of the ATP binding site, hMTHFS was mixed with ATP before setting up crystallization drops. Electron density for the purine ring and the sugar moiety of the ATP was weak and only the phosphates could be modeled accurately (Fig. 2A and C). In the crystal structures of mpMTHFS and hMTHFS, the adenosine and sugar are lying on the surface and have very little contact with the protein. On the other hand, the phosphates are buried deep inside the protein and are involved in extensive ionic interactions. The structure of hMTHFS bound with phosphates (referred to as ADP-bound hMTHFS) is almost identical to the structure of the apoenzyme.

**Table 1. Relative activities of hMTHFS mutants**

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Location</th>
<th>Relative activity (%)</th>
<th>Conservation</th>
</tr>
</thead>
<tbody>
<tr>
<td>K10A</td>
<td>ATP binding site</td>
<td>7.5</td>
<td>Highly conserved</td>
</tr>
<tr>
<td>R14A</td>
<td>ATP binding site</td>
<td>12.9</td>
<td>Highly conserved</td>
</tr>
<tr>
<td>R145A</td>
<td>ATP binding site</td>
<td>2.3</td>
<td>Absolutely conserved</td>
</tr>
<tr>
<td>D154A</td>
<td>ATP binding site</td>
<td>0.9</td>
<td>Absolutely conserved</td>
</tr>
<tr>
<td>F55A</td>
<td>Close to pterin ring</td>
<td>53.6</td>
<td>Conserved</td>
</tr>
<tr>
<td>M58A</td>
<td>Close to pterin ring</td>
<td>121.6</td>
<td>None</td>
</tr>
<tr>
<td>E61A</td>
<td>Close to pterin ring</td>
<td>8.6</td>
<td>Absolutely conserved</td>
</tr>
<tr>
<td>Y83A</td>
<td>Close to pterin ring</td>
<td>100</td>
<td>None</td>
</tr>
<tr>
<td>M90A</td>
<td>Close to pterin ring</td>
<td>49.2</td>
<td>Conserved</td>
</tr>
<tr>
<td>Y132A</td>
<td>Close to pterin ring</td>
<td>24.9</td>
<td>Highly conserved</td>
</tr>
<tr>
<td>Y153A</td>
<td>Close to pterin ring</td>
<td>3.2</td>
<td>Absolutely conserved</td>
</tr>
<tr>
<td>F95A</td>
<td>Close to pABA ring</td>
<td>72.3</td>
<td>None</td>
</tr>
<tr>
<td>W109A</td>
<td>Close to pABA ring</td>
<td>39.7</td>
<td>None</td>
</tr>
<tr>
<td>R148A</td>
<td>Close to pABA ring</td>
<td>30.7</td>
<td>None</td>
</tr>
<tr>
<td>K150A</td>
<td>Close to pABA ring</td>
<td>100</td>
<td>None</td>
</tr>
</tbody>
</table>

**Cancer Res 2009; 69: (18). September 15, 2009 7296 www.aacrjournals.org**

**NOTE:** Level of conservation has been assigned according to Clustal W convention (37). The top 100 sequences of MTHFS homologues obtained by running a PSI-BLAST search were curated by removing hypothetical and redundant sequences and aligned using Clustal W.
the loop (A174-D193) region, part of which is disordered in the structure of the apoenzyme.

To gain a better understanding of the structural basis for substrate binding and the underlying mechanism of catalysis, we cocrystallized hMTHFS with ATP and 5-formyltetrahydrofolate. Interestingly, analysis of the electron density for the 5-formyltetrahydrofolate substrate, coupled with the results of a search for the anomalous signal of phosphate, revealed a phosphate group covalently linked to the carbon atom belonging to the formyl group of the 5-formyltetrahydrofolate. During the course of the cocrystallization (carried out at 16°C for 48 hours), the formyl group of the substrate seems to have completed a nucleophilic attack at the γ-phosphate of the ATP, resulting in the formation of the N5-iminium phosphate reaction intermediate, which was fortuitously trapped inside the crystal used for data collection. The structure of the enzyme-product complex of hMTHFS was obtained by harvesting the crystals produced during the cocrystallization of hMTHFS with 5-formyltetrahydrofolate and ATP after 72 hours. Except for the conformation of the side chains of Y83, F85, and Y152, the overall structure of the enzyme-product complex of hMTHFS is similar to the structures of native hMTHFS and N5-iminium phosphate–bound hMTHFS. A notable difference is the movement of the side chain of Y83, which has implications on the catalysis (Fig. 2D).

The structure of the enzyme-product complex of hMTHFS was obtained by harvesting the crystals produced during the cocrystallization of hMTHFS with 5-formyltetrahydrofolate and ATP after 72 hours. Except for the conformation of the side chains of Y83, F85, and Y152, the overall structure of the enzyme-product complex of hMTHFS is similar to the structures of the apoenzyme and ADP-bound complex of hMTHFS. A notable difference is the movement of the side chain of Y83, which has implications on the catalysis (Fig. 2D).

**Folate binds in a spherical pocket.** The pterin ring of the N5-iminium phosphate moiety sits in the center of a large spherical binding pocket formed by residues F55, L56, S57, M58, E61, P81, Y83, M90, W109, P135, R148, K150, Y152, and Y153 (Fig. 3A). The short helix (α4) and a long loop inserted between strands β3 and β4 act like a cap and are seen partially covering the active site. W109 is positioned above the pterin ring and seems to be closing the lid on the active site. The distance between the two aromatic rings is >7 Å, suggesting that W109 and the pterin ring do not interact. The conformation of the pterin ring is not planar. It is raised at the C6 position along the vertical axis (Fig. 3B). The twisting of the pterin ring probably helps bring the reacting functional groups in close proximity and adjust their orientation. The carboxyl oxygens of E61 are interacting with the N3 and amine nitrogens of the pterin ring. This interaction is of interest because the glutamic acid at this position is conserved in all the orthologs of MTHFS (Supplementary Fig. S1). M90 forms a hydrogen bond with the N8 nitrogen of the pterin ring. Numerous hydrophobic van der Waals contacts are observed between the pterin ring and the aromatic side chains of F55, Y83, P135, Y152, and Y153. Interestingly, the conformation of the aromatic ring of Y83 is distinctly different in the structures of native hMTHFS and N5-iminium phosphate–bound hMTHFS (Fig. 2D). The side chain swivels and occupies an upright position, which allows the pterin ring to dock in the binding pocket. This movement of the side chain of Y83 in turn displaces the side chain of F85 away from the binding pocket.

Further, the binding pocket is large enough to accommodate the pABA moiety of the substrate, which is almost perpendicular to the pterin ring. W109 and K150 form hydrogen bonds with the pABA ring. The glutamate protrudes out of the binding pocket through a circular hole at the top and is lying on the surface of the protein.
Adjacent to the hole is a large patch of positively charged potential, which may be involved in the binding of polyglutamates (Fig. 2C).

**ATP binding site.** hMTHFS contains an ATP binding site, which is distinct but in proximity to the substrate binding site (Figs. 2C and 3A). Based on the position of the phosphates, ATP binds in a positively charged cleft region between strand β6 and helix α5. The α- and β-phosphates are tethered in the ATP binding cleft by coordinate bonds with magnesium on one side and cohesive ionic bonds on the opposite side. K10 forms an ionic bond with the O2 atom of the α-phosphate, whereas R14 forms an ionic bond with the O1 atom of the β-phosphate. These residues are important for the docking of the ATP. The γ-phosphate forms two ionic bonds with R145. This interaction is critical for the correct orientation of the γ-phosphate in order for it to be able to mount a nucleophilic attack on the substrate and may also be essential for the stabilization of the intermediate. The ATP binding cleft is connected to the spherical tetrahydrofolate binding site internally through a channel such that the γ-phosphate of the ATP molecule is positioned close to the N5 atom of the pterin ring (Fig. 3C).

**Enzyme-product complex.** The structure of the enzyme-product complex was determined by delaying the harvest time of crystals obtained during cocrystallization of hMTHFS with 5-formyltetrahydrofolate and ATP. The overall structure of the hMTHFS bound with product is almost identical to the other structures of hMTHFS. Notably, the conformation of the side chains of Y83 and Y152 is distinctly different (Fig. 2D). In the structure of the N5-iminium phosphate–bound hMTHFS, we have seen that the aromatic ring of Y83 moves by 120° to make way for the substrate.
to dock (Fig. 2D). In the enzyme-product complex, the aromatic ring of Y83 moves further 125° and is now seen forming a 2.4 Å hydrogen bond with the side chain nitrogen of N88. As a consequence of this movement, the aromatic ring of Y152 is displaced by 100° (Fig. 2D). The side chain of F85 seen displaced in the N5-iminium phosphate–bound hMTHFS structure returns back to its original position (Fig. 2D).

An interesting aspect of the study of the enzyme-product complex of hMTHFS was the analysis of the electron density for the product. The density was not continuous between the N5 and N10 atoms, and therefore, the product 5,10-methenyltetrahydrofolate could not be modeled. Instead, a formyl group could be modeled accurately in the extra density seen at the N10 position, suggesting the presence of 10-formyltetrahydrofolate rather than 5,10-methenyltetrahydrofolate in the active site of hMTHFS (Fig. 2D). 5,10-Methenyltetrahydrofolate has been reported to degrade non-enzymatically to 10-formyltetrahydrofolate previously (1, 34).

Increasing the expression of MTHFS in SHSY-5Y cells increased the levels of 10-formyltetrahydrofolate to as much as 90% of the total cellular folate with a concomitant decrease in the levels of 5-formyltetrahydrofolate, suggesting that MTHFS may be able to catalyze the conversion of 5-formyltetrahydrofolate to 10-formyltetrahydrofolate (35). This is the first structural evidence for the synthesis of 10-formyltetrahydrofolate from 5-formyltetrahydrofolate by hMTHFS.

**Structure-function analysis.** Using the structures of hMTHFS as a guide, we selected and probed the role of residues surrounding the substrate and ATP binding site in catalysis by site-directed mutagenesis (Table 1). Wild-type and mutant hMTHFS were purified to homogeneity before testing the activity under identical conditions. We interpret and discuss the results of mutagenesis in light of the structures of hMTHFS, mpMTHFS, and bMTHFS. Equivalent positions for the hMTHFS residues in mpMTHFS and bMTHFS have been identified by superimposing the structures of
residues probably assist in isolating the reactants from the mutation resulted in over 60% loss in activity (Table 1). These activity for the F85A mutation was only marginal. W109A mutation almost completely abolished enzymatic activity. The OD1 and OD2 oxygens of D154 are hydrogen bonded to the magnesium ion and are part of the octahedral coordination shell of magnesium. This interaction is critical because the magnesium ion is hydrogen bonded to α- and β-phosphates of the ATP, which participates in the catalysis. K10, R14, R145, and D154 occupy identical positions in the hMTHFS, mpMTHFS, and bMTHFS structures. K10 and R14 are highly conserved, whereas R145 and D154 are absolutely conserved among orthologs of MTHFS (Supplementary Fig. S1). Thus, MTHFS tethers the phosphates of ATP using a highly conserved mechanism. The role of residues F55, E61, Y83, M90, Y153, M58, and R148 surrounding the pterin ring of tetrahydrofolate was investigated by mutating them to alanine (Table 1). Interestingly, the E61A and Y153A mutations almost completely abolished the enzymatic activity. In the structure of hMTHFS bound with N5-iminium phosphate, the carboxyl oxygens of E61 are interacting with the C2 amino group and the N3 nitrogen. These interactions are probably critical for anchoring the substrate in the binding pocket. Y153 is positioned below the pterin ring and defines the bottom edge of the binding pocket. Both E61 and Y153 are seen occupying identical positions in hMTHFS, mpMTHFS, and bMTHFS structures and are absolutely conserved in MTHFS orthologs (Supplementary Fig. S1). Although the M90A and R148A mutations did not abolish the enzymatic activity completely, >50% of the activity was compromised, indicating that the longer side chains at this position could increase the efficiency of catalysis of hMTHFS. M90 is replaced by an isoleucine in mpMTHFS. Interestingly, R148 has been changed to a phenylalanine and a tyrosine in mpMTHFS and bMTHFS, respectively. The arginine at this location is not highly conserved among the orthologs of MTHFS. Notably, the orthologs have only two choices at this position: an aromatic amino acid or an arginine (Supplementary Fig. S1). Because R148 is close to the pABA ring, replacing it with an aromatic amino acid could initiate stacking interactions with the pABA ring and promote the nucleophilic attack of N10 on the N5-iminium phosphate. The F55A mutation resulted in >45% loss in enzyme activity (Table 1), suggesting that a hydrophobic residue may be essential at this position for efficient catalysis. F55 is replaced by a tyrosine in mpMTHFS and a threonine in bMTHFS. Sequence alignment results reveal that this position is occupied by a hydrophobic residue in the orthologs of MTHFS. Y83 and M58 do not seem to be essential for catalysis because the enzyme activity did not decrease after mutating either of them to alanine. A valine is present at the position of Y83 in mpMTHFS, whereas a cysteine occupies an equivalent position in the structure of bMTHFS. M58 is replaced by an isoleucine in mpMTHFS. In the structure of native hMTHFS, F85 and W109 form a cap over the active site. The decrease in activity for the F85A mutation was only marginal. W109A mutation resulted in over 60% loss in activity (Table 1). These residues probably assist in isolating the reactants from the solvent during catalysis. A serine replaces the phenylalanine in mpMTHFS, whereas a lysine is seen at a similar position in bMTHFS. W109 is part of a long insertion (E96-G117), which is not seen in mpMTHFS. A tyrosine is present at a similar location in the bMTHFS. Further, the Y152A mutation lowered the enzyme activity by over 75% (Table 1). Y152 is close to the pterin ring and may be important for the correct orientation of the ring or the integrity of the binding pocket. The position of the side chain of Y152 is different in the native and enzyme-product complex structures of hMTHFS, suggesting a role for Y152 in product release. Y152 is conserved in the mpMTHFS and bMTHFS. A majority of the orthologs of MTHFS have a tyrosine at this position, with an occasional occurrence of phenylalanine (Supplementary Fig. S1). The K150A mutation did not have any effect on enzyme activity, suggesting that K150 is not essential for catalysis. K150 is replaced by a glycine in the bMTHFS.

**Discussion**

**Determinants of ligand specificity.** An interesting aspect of the native hMTHFS is the location of the side chain of Y83 inside the binding pocket. The aromatic ring of Y83 sterically obstructs the placement of the pterin ring inside the pocket (Fig. 2D). In the structure of the N5-iminium phosphate–bound hMTHFS, the side chain of Y83 has moved by 120°, allowing the placement of the pterin ring inside the pocket. Obviously, the Y83 somehow recognizes the substrate and moves. Such a mechanism of substrate binding offers greater selectivity by occluding functional groups that are not compatible or those that cannot be “recognized” by the side chain of Y83. Mutating Y83 to alanine had no effect on enzyme activity, suggesting that the role of Y83 is dispensable.

**Structural basis for inhibition of hMTHFS by N10-substituted folate analogues.** hMTHFS has been reported to be feedback inhibited by 10-formyltetrahydrofolate (22). Analysis of the structure of the enzyme-product complex of hMTHFS reveals that the synthesis or binding of 10-formyltetrahydrofolate places the formyl group of N10 within van der Waals radii of Y83. Therefore, to avoid steric clashes, Y83 moves by 125° from its position seen in the N5-iminium phosphate reaction intermediate-bound hMTHFS (Fig. 4A and B). The movement of Y83 displaces Y152, which moves away from Y83 to avoid steric clashes. This places Y152 in front of the channel connecting the ATP binding site with the substrate binding pocket. Y152 blocks the channel, obstructing any further nucleophilic attacks by the γ-phosphate of ATP (Fig. 4A and B). More importantly, the Y152 could preclude the formation of the γ-phosphate of ATP within hydrogen bonding distance of N5 owing to steric hindrance. Therefore, tetrahydrofolates with N10 substitutions can act as potential inhibitors of MTHFS activity (23). Our study provides for the first time the structural basis for this inhibition. The structure of the N5-iminium phosphate–bound hMTHFS not only contributes toward the unraveling of the basis for this inhibition but also helps explain why Y83 may be unobtrusive during catalysis of 5-formyltetrahydrofolate to 5,10-methylenetetrahydrofolate. This further underscores the importance of having reaction intermediates while studying reaction mechanisms.

In conclusion, the structures of hMTHFS determined by us provide a clear picture of the folate and ATP binding pockets. The snapshot of the N5-iminium phosphate–bound hMTHFS accounts for the first intermediate formed during the conversion
of 5-formyltetrahydrofolate to 5,10-methylenetetrahydrofolate. The structure of the enzyme-product complex of hMTHFS reveals new features of hMTHFS-mediated catalysis. This study provides for the first time structural evidence for the synthesis of 10-formyltetrahydrofolate from 5-formyltetrahydrofolate by hMTHFS. From our structural studies, we can begin to rationalize the basis for inhibition of hMTHFS by 10-formyltetrahydrofolate and N10-substituted antifolates. We have identified amino acids critical for catalysis by site-directed mutagenesis. The structural, mutagenesis, and primary sequence analysis data of MTHFS orthologs suggest a highly conserved mechanism of catalysis. The structures of the essential hMTHFS reported here open up new opportunities for rationally designing antifolates or small molecules to combat the proliferation of cells.

Disclosure of Potential Conflicts of Interest

The authors declare they have no conflicts of interest.

Acknowledgments

Received 5/27/09; revised 6/26/09; accepted 7/9/09; published OnlineFirst 9/8/09.

Grant support: Ministry of Science and Technology of China grants 2006AA02A316, 2006CB910901, and 2009DF03010. National Natural Science Foundation of China grants 30870483, 30704722, and 30721003; Ministry of Health of China grant 2008ZX10004-015; and CAS Research grant KSCX2-YW-R-127.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Xudong Zhao of the core facilities center at IBP for technical assistance.

Crystallographic data were collected at the Structural Biology Center beamline 19-ID (Advanced Photon Source, Argonne National Laboratory) and the Shanghai Synchrotron Radiation Facility beamline BL17U.

References

Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues

Dong Wu, Yang Li, Gaojie Song, et al.

Cancer Res  Published OnlineFirst September 8, 2009.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-09-1927

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2009/09/04/0008-5472.CAN-09-1927.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2008/12/31/0008-5472.CAN-09-1927.citation. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.